VelosBio Inc. is a next-generation oncology company, developing novel antibody-drug conjugates (“ADCs”) to treat haematological cancers and solid tumours.
VelosBio was acquired by Merck & Co for $2.75bn in December 2020.
Keep browsing through the other companies in our portfolio.